Endocrine Abstracts

Introduction: Different studies have published that testosterone therapy in men and women results in decreased HDL cholesterol and increased LDL cholesterol, and therefore an increased cardiovascular risk.Aims: To determine whether testosterone therapy has this effect on lipid parameters and markers of metabolic syndrome (MetSyn) in female-to-male transsexuals (FMT).Material and methods: We studied 50 FMT, aged 27.8±7.6 years,...

Background: Cushing’s syndrome (CS) is considered to be more frequent among patients with metabolic syndrome. Previous studies have suggested to perform a routine screening for CS in obese patients; however, more recent reports only recommend a case-finding approach in patients with uncontrolled diabetes and hypertension, despite appropriate treatment.Objective: The aim of this study was to evaluate the prevalence of unsuspected CS in morbidly obese...

Introduction: The transsexuals are persons that having born with a biological sex feel to belong to the opposite sex. To obtain the sexual characters opposite to his (her) biological sex they need treatment with cross-sex hormones.This treatment with sexual steroids can produce changes in cardiovascular risk factors (CRF). There has been described that hyperhomocysteinemia is an independent CRF that is modifiable by cross-sex hormonal treatment (CHT) in ...

Moderately elevated body iron stores may be associated with several components of the metabolic syndrome (MetSyn). Elevated serum ferritin levels (Fer) independently predicted incident type 2 diabetes in prospective studies in apparently healthy men and women.Aims: To analyze the association between Fer and components of MetSyn in transsexuals before and after 2-year cross-sex treatment (CST).Methods: Before starting the CST in 90 ...

Elevated serum ferritin levels has been reported in premenopausal women presenting polycystic ovary syndrome (PCOS) and hyperandrogenism, and thus may be involved in the development of insulin resistance, type 2 diabetes y cardiovascular disease. In female-to-male transsexuals (FMTs) PCOS is frequent and this issue has been little studied.Aims: To study the serum ferritin in FMTs with PCOS and their relations with markers of insulin resistance (IR) and m...

Abiraterone acetate is a potent, selective inhibitor of CYP17, a key enzyme that catalyses the conversion of pregnenolone to dehydroepiandrosterone (DHEA) and progesterone to androstenedione. Inhibition of this enzyme causes suppression of the synthesis of both androgens and oestrogens. Hence treatment with abiraterone acetate could impact on the development and progression of hormone-dependent breast and prostate cancers.In a phase I/II1,2 st...

Introduction: Adrenal tumors are common tumors with a prevalence of around 3% in a population over the age of 50 years. In contrast, adrenocortical carcinoma (ACC) is a rare malignancy (incidence 1–2 per 1 million population) with a heterogeneous presentation and a variable but generally bad prognosis. Patients present with evidence of adrenal steroid hormone excess in approximately 60% of cases.Case report: A 49-year-old woman with symptoms of faci...

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...

Introduction: Type 1 diabetes mellitus (T1DM) is considered, in general, a disease of children and young adults with normal body mass index (BMI), linked to a genetic susceptibility based on autoimmunity. However, we know that it can be diagnosed at any age and we must differentiate it from type 2 diabetes mellitus.Objetives: To investigate the phenotypic characteristics and the presence of specific autoimmunity in T1DM patients diagnosed in our hospital...

Introduction: New long-acting insulin analogues (insulin degludec –ID- and insulin glargine 300 U/ml –IG300-) have proved, in clinical trials, that improve metabolic control with lower hypoglycemia rate in T2D.Objective: To assess characteristics of T2D patients who were given ID and IG300 and to evaluate their effect on metabolic control, weight and insulin dose.Material and methods: We studied T2D patients whose treatme...